Shanghai, China –Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") recently reached a strategic agreement with Wuhan Asian Industrial Co, Ltd. ("Wuhan Asian Industrial") at a meeting of Innovative Cooperation Under the New Environment and New Opportunities in Shanghai. MicroPort® Chairman & Chief Executive Officer Dr. Zhaohua Chang and Wuhan Asian Industrial Chairman & General Manager Junming Xie signed the agreement on behalf of the two companies at the headquarter of MicroPort.
MicroPort® and Wuhan Asian Industrial reached the strategic agreement in order to cooperate in the research and development of new technology and new product in the medical device industry. The two parties will strengthen their cooperation in clinical study and technology to better foresee the industry development trend and identify unsatisfied clinical needs. At the same time, the bilateral cooperation will help promoting the development of the industrialization projects. According to the agreement, the relatively mature techniques that Wuhan Asian Industrial acquired from its clinical study will be shown to and evaluated by Microport®, which will then provide its assessment advice on industrialization. The two parties will actively explore and implement possible industrialization projects by sharing resources and leveraging complementary advantages in R&D and clinical study.
MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. Wuhan Asian Industrial is a medical device company with business focusing on research, development and production. It also owns several renowned cardiology specialized hospitals in China with Wuhan Asia Heart Hospital (WAHH) being the first non-profit private-owned one. WAHH's annual surgical operation amount has been top 1 in Hubei Province and among the top three in the nation for 14 consecutive years. By giving full play of bilateral advantages in product R&D and clinical areas, this partnership will help promote innovation and development to provide safe, effective and affordable high-end product and quality service for patients.